ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,453,758, issued on Oct. 28, was assigned to ELI LILLY AND COMPANY (Indianapolis).
"Method of using a GIP/GLP1 co-agonist for diabetes" was invented by Jorge Alsina-Fernandez (Indianapolis), Over Cabrera (Carmel, Ind.) and Tamer Coskun (Carmel, Ind.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Furthermore, the present invention provides methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 rec...